Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) ‐ outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients
Shuangtao Zhao(The University of Texas MD Anderson Cancer Center), Preetesh Jain(The University of Texas MD Anderson Cancer Center), Wendy Chen(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center), Krystle Nomie(The University of Texas MD Anderson Cancer Center), Raphel Steiner(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Lucy Navsaria(The University of Texas MD Anderson Cancer Center), Xingzhi Song(The University of Texas MD Anderson Cancer Center), Swaminathan P. Iyer(Houston Methodist), Luis Fayad(The University of Texas MD Anderson Cancer Center), Dapeng Hao(The University of Texas MD Anderson Cancer Center), Selvi Thirumurthi(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Guangchun Han(The University of Texas MD Anderson Cancer Center), Nathan Fowler(The University of Texas MD Anderson Cancer Center), Yixin Yao(The University of Texas MD Anderson Cancer Center), Linghua Wang, Chi Young Ok(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Omar Moghrabi(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Changying Jiang, Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(CancerCare Manitoba), Holly A. Hill(The University of Texas MD Anderson Cancer Center), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), Jianhua Zhang(WiCell), Michael Wang(The University of Texas MD Anderson Cancer Center), Shaojun Zhang(The University of Texas MD Anderson Cancer Center), Guofan Xu(The University of Texas MD Anderson Cancer Center), Shaoying Li(The University of Texas MD Anderson Cancer Center), Leonard Jeffrey Medeiros(The University of Texas MD Anderson Cancer Center), Jorge Moreno Aranda(The University of Texas MD Anderson Cancer Center), Maria Badillo(The University of Texas MD Anderson Cancer Center), Onyeka Oriabure(The University of Texas MD Anderson Cancer Center), C. Cameron Yin(The University of Texas MD Anderson Cancer Center), Ranjit Nair(The University of Texas MD Anderson Cancer Center), Francisco Vega(The University of Texas MD Anderson Cancer Center)
Cited by 84
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k